18:56 , Nov 16, 2018 |  BC Week In Review  |  Company News

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report . ICER said...
16:01 , Nov 16, 2018 |  BC Week In Review  |  Company News

MEI Pharma outlicenses PI3K inhibitor to Kyowa in Japan, BeiGene in China

MEI Pharma Inc. (NASDAQ:MEIP) granted Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) exclusive rights in Japan to develop and commercialize ME-401, initially for relapsed or refractory follicular lymphoma. ME-401 is a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor....
22:33 , Nov 15, 2018 |  BC Innovations  |  Translation in Brief

The bystander effect of Treg depletion

Limiting bystander effects of immunosuppressive Treg-targeting therapies may be crucial for their antitumor efficacy, according to data released last week at the Society for Immunotherapy of Cancer meeting. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) presented...
20:00 , Nov 2, 2018 |  BC Week In Review  |  Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the...
13:46 , Nov 1, 2018 |  BC Extra  |  Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the...
22:43 , Oct 26, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
17:57 , Sep 28, 2018 |  BC Week In Review  |  Company News

ICER finds asthma mAbs to be not cost-effective

In a draft evidence report , the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies...
17:25 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

EMA's CHMP on Sept. 21 recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam. CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta...